Clinical relevance of cyclooxygenase 2 and peroxisome proliferator-activated receptor γ in eyelid sebaceous gland carcinoma

Histopathology
P JayarajMansi Verma

Abstract

Sebaceous gland carcinoma (SGC) is a malignancy associated with the pilosebaceous unit, and occurs at ocular or non-ocular sites. Cyclooxygenases (COXs) are enzymes that are crucial for lipid metabolism. COX-2 is overexpressed in various cancers, and its inhibition by non-steroidal anti-inflammatory drugs is known to reduce the risk of many cancers. Peroxisome proliferator-activated receptor (PPAR)-γ is a transcription factor involved in adipogenesis. PPAR-γ is a potential therapeutic target for the treatment of malignant tumours, including colon carcinoma. The aim of this study was to explore the status of COX-2 and PPAR-γ as prognostic markers in human eyelid SGC. The immunohistochemical expression of COX-2 and PPAR-γ was evaluated in 31 SGC cases. Cytoplasmic expression of COX-2 was detected in 80% of the SGC cases, and nuclear expression of PPAR-γ in 87%. There were significant correlations of PPAR-γ expression with well-differentiated SGC [19/21 (90%)] and of COX-2 overexpression with reduced disease-free survival (P = 0.0441, log rank analysis). COX-2 expression [odds ratio (OR) 3.82, 95% confidence interval (CI) 1.02-14.33, P = 0.046] and lymph node metastasis (OR 0.17, 95% CI 0.04-0.65, P = 0.009) emerged as significant...Continue Reading

References

Feb 1, 1984·Archives of Ophthalmology·M T Doxanas, W R Green
Jul 1, 1995·Journal of the American Academy of Dermatology·B R NelsonT M Johnson
Jan 1, 1996·Archives of Ophthalmology·R SihotaR Arora
Jul 14, 1998·Molecular Cell·E MuellerB M Spiegelman
Sep 14, 2000·Proceedings of the National Academy of Sciences of the United States of America·E MuellerP W Kantoff
Apr 28, 2001·Neoplasia : an International Journal for Oncology Research·O GalloE Masini
Jun 21, 2001·Proceedings of the National Academy of Sciences of the United States of America·G NeufangK Müller-Decker
Jun 22, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G DaviesM Dowsett
Sep 11, 2002·Proceedings of the National Academy of Sciences of the United States of America·Karin Muller-DeckerGerhard Furstenberger
Aug 15, 2003·Molecular and Cellular Biology·Chenguang WangRichard G Pestell
Dec 12, 2003·Nature Reviews. Drug Discovery·Garret A FitzGerald
Jul 24, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Panayiotis A KyzasNiki J Agnantis
Jun 22, 2005·Prostaglandins & Other Lipid Mediators·Kirsi NarkoTimothy Hla
Jan 19, 2006·The Journal of Investigative Dermatology·Qiwei ZhangRaymond L Konger
Feb 24, 2006·Nature Reviews. Cancer·Cornelia M UlrichJohn D Potter
Mar 28, 2006·Nature Medicine·Hikaru TakedaFiona M Watt
May 23, 2006·Anti-cancer Agents in Medicinal Chemistry·Aurélie TelliezJean-Pierre Hénichart
Aug 3, 2006·Journal of Clinical Pathology·K O AlsaadD Ghazarian
Jun 28, 2008·PPAR Research·Keisuke TachibanaTakefumi Doi
Jul 23, 2008·Molecular Cancer Therapeutics·Francescopaolo Di CelloLinda M S Resar
Feb 4, 2010·Blood·Alejandro GutierrezA Thomas Look
Jun 21, 2012·Head & Neck·Boban M ErovicJonathan C Irish
Dec 12, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Corinne M DollAnthony M Magliocco
Jan 29, 2014·Carcinogenesis·Jing JiaoHarvey Herschman

❮ Previous
Next ❯

Citations

Apr 27, 2018·International Ophthalmology·Maria Vittoria Cicinelli, Swathi Kaliki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

© 2022 Meta ULC. All rights reserved